| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/27/2008 | CN101130081A Use of PNAS-4 gene in preparing antineoplastic and antineoplastic auxiliary medicament |
| 02/27/2008 | CN101130080A Gelling agent for controlling and releasing 5-HT* acceptor antagon and method of preparing the same |
| 02/27/2008 | CN101129521A Effective component of hedyotis diffusa and method of preparing the same and application |
| 02/27/2008 | CN101129359A Pharmaceutical composition containing amoxicillin, ambroxol and beta lactamase restrainer and uses thereof |
| 02/27/2008 | CN101129357A Pharmaceutical composition containing fipronil and application of the same in preparing medicament for killing auricular mite for animals |
| 02/27/2008 | CN101129344A Methods, assays and compositions for treating retinol-related diseases |
| 02/27/2008 | CN101129342A Method of producing hepatic targeting drug microcapsule |
| 02/27/2008 | CN100371714C Methods and compositions for treatment of central nervous system disorders |
| 02/27/2008 | CN100371442C Ligand/receptor specificity exchangers that redirect antibodies to receptors on pathogen |
| 02/27/2008 | CN100371348C Treatment of micro-organism infection |
| 02/27/2008 | CN100370989C Use of 5-HT5-ligands in treatment of neurodegenerative and neuropsychiatric disturbances |
| 02/27/2008 | CN100370965C Cleansing composition containing antifungal agent and antibacterial agent |
| 02/26/2008 | US7335756 Isolated nucleic acid comprising polynucleotide of given sequence; diagnostic kits; use in treatment of cancer |
| 02/26/2008 | US7335727 fusion inhibitor; high stability and high valence; higher efficacy, and lower administration dosage, and thereby lower toxicity. |
| 02/26/2008 | US7335725 Lipopeptides as antibacterial agents |
| 02/26/2008 | US7335683 Compositions and methods for cystic fibrosis therapy |
| 02/26/2008 | US7335680 Preterm labor, dysmenorrhea, asthma, hypertension, fertility disorder, sexual dysfunction, undesired blood clotting, bone disorders, preeclampsia or eclampsia, or an eosinophil disorder; use with phosphodiesterase inhibitors; e.g. 7-[(2R,3R)-3-Chloro-1-(4-hydroxynonyl)-pyrrolidin-2-yl]-hept-5-enoic acid |
| 02/26/2008 | US7335664 Ingesting bisacodyl, metoclopramide, phosphorus compound and sodium; kits |
| 02/26/2008 | US7335649 3-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxy-3'-(tetrazol-5-yl)biphenyl for treatment of thrombocytopenia; colony stimulating factors |
| 02/26/2008 | US7335648 Thrombosis; anticoagulants; renal dialysis |
| 02/26/2008 | US7335637 Biglycan and related therapeutics and methods of use |
| 02/26/2008 | US7335635 14-3-3 binding molecules as sensitizers for anticancer therapies |
| 02/26/2008 | US7335505 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 02/26/2008 | US7335499 tRNA synthetase |
| 02/26/2008 | US7335371 Combinations for the treatment of inflammatory disorders |
| 02/26/2008 | US7335355 Antimicrobial agent |
| 02/26/2008 | US7335354 Methods for the reduction of malignant tumors by an eosinophil/helminth therapy |
| 02/26/2008 | US7335350 Treating multiple sclerosis by orally administering an excipient and a RANTES polypeptide; preventing autoimmune and inflammatory diseases and bacterial and viral infections |
| 02/26/2008 | CA2430592C New pharmaceutical compositions based on anticholinergics and dopamine agonists |
| 02/26/2008 | CA2382292C Ibuprofen-containing softgels |
| 02/26/2008 | CA2363124C Use of aromatic polycyclic compounds as activators of ppars-type receptors in a cosmetic or pharmaceutical composition |
| 02/26/2008 | CA2284142C Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
| 02/26/2008 | CA2200761C Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound |
| 02/21/2008 | WO2008021729A2 Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases |
| 02/21/2008 | WO2008021728A2 Treating infections and sequelae thereof with combined dissociated' glucocorticoid receptor agonists and anti-infective agents |
| 02/21/2008 | WO2008021532A2 Treatment of inflammatory diseases |
| 02/21/2008 | WO2008021389A2 Using pi3k and mek modulators in treatments of cancer |
| 02/21/2008 | WO2008021124A2 Compositions and drug-delivery systems comprising rapamycin analogs and paclitaxel |
| 02/21/2008 | WO2008020651A1 P2x4 receptor antagonist |
| 02/21/2008 | WO2008020489A1 Remedy for inflammatory bowel disease |
| 02/21/2008 | WO2008020306A2 Isoindole derivatives |
| 02/21/2008 | WO2008020150A1 Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs |
| 02/21/2008 | WO2008020085A2 Use of chloro- and fluoromethyl ketone derivatives in anti-viral therapy |
| 02/21/2008 | WO2008020040A2 2,5-dihydroxybenzene compounds for the treatment of fibrosis |
| 02/21/2008 | WO2008020039A2 2,5-dihydroxybenzene compounds for treating cancers and hematological dyscrasias |
| 02/21/2008 | WO2008020030A1 2,5-dihydroxybenzene compounds for the treatment of psoriasis |
| 02/21/2008 | WO2008020028A1 2,5 dihydroxybenzene compounds for the treatment of rosacea |
| 02/21/2008 | WO2008020027A2 2,5-dihydroxybenzene compounds for the treatment of skin cancer |
| 02/21/2008 | WO2007144501A3 Use of a vasopeptidase inhibitor for the treatment of pulmonary arterial hypertension |
| 02/21/2008 | WO2007122419A3 Therapeutic method for glycaemic control |
| 02/21/2008 | WO2007112065A3 Methods for treating cognitive and other disorders |
| 02/21/2008 | WO2007068934A3 Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
| 02/21/2008 | WO2007027560A8 Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents |
| 02/21/2008 | WO2007014238A8 Single dose use of cd20-specific binding molecules |
| 02/21/2008 | US20080045611 Methods for the therapeutic use of a carbonic anhydrase inhibitor for reducing spinal cord edema |
| 02/21/2008 | US20080045610 Methods for regulating neurotransmitter systems by inducing counteradaptations |
| 02/21/2008 | US20080045608 Gene Encoding a Guanine Nucleotide Exchange Factor Binding to Rhoa |
| 02/21/2008 | US20080045607 Compositions and Methods for Treatment of Protein Misfolding Diseases |
| 02/21/2008 | US20080045567 Therapeutic Agent for Hyperlipemia and Therapeutic Agent for Diabetes |
| 02/21/2008 | US20080045565 Combinations Comprising Antimuscarinic Agents and Beta-Adrenergic Agonists |
| 02/21/2008 | US20080045480 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| 02/21/2008 | US20080044472 Photoresponsive Hydrogels |
| 02/21/2008 | US20080044471 Neurotherapeutic compositions |
| 02/21/2008 | US20080044464 Liposome loading with metal ions |
| 02/21/2008 | US20080044409 Inflammatory mediator antagonists |
| 02/21/2008 | US20080044390 Methods and compositions for the treatment of neurodegenerative disorders |
| 02/21/2008 | US20080044380 Hepatitis C Virus Inhibitors |
| 02/21/2008 | US20080044377 Poxvirus Vector Encoding Retrovirus (Eg Hiv) And Cytokine |
| 02/21/2008 | US20080044353 Combination Therapy for Weight Management |
| 02/21/2008 | DE102006039148A1 Verwendung von Chloro- und Fluoromethylketon-Derivaten in der anti-viralen Therapie Using chloroform and Fluoromethylketon derivatives in the anti-viral therapy |
| 02/21/2008 | CA2660880A1 Treatment of inflammatory diseases |
| 02/21/2008 | CA2659424A1 Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs |
| 02/21/2008 | CA2658725A1 Using pi3k and mek modulators in treatments of cancer |
| 02/20/2008 | EP1890151A1 Oncolytic viruses as phenotyping agents for neoplasms |
| 02/20/2008 | EP1889905A1 Method for amelioration of disease condition induced by mood disorder |
| 02/20/2008 | EP1889842A1 Heterocyclic compound |
| 02/20/2008 | EP1889839A1 Bicyclic compound, production and use as HIV inhibitors |
| 02/20/2008 | EP1889838A1 Thrombopoietin mimetics |
| 02/20/2008 | EP1889633A1 Medicinal compositions for angiogenic therapy |
| 02/20/2008 | EP1889631A1 Cell growth inhibition |
| 02/20/2008 | EP1889624A2 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites |
| 02/20/2008 | EP1889618A1 Combined drug for treating diabetes |
| 02/20/2008 | EP1889614A2 Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction |
| 02/20/2008 | EP1889613A1 Pharmaceutical composition comprising vitamin k |
| 02/20/2008 | EP1888624A2 Method of purifying apo-2 ligand/trail using crystallisation in the cold |
| 02/20/2008 | EP1888568A2 Substituted benzimidazole compounds with dual nos inhibitory activity and muopioid agonist activity |
| 02/20/2008 | EP1888173A2 Novel use of (-)-epigallocatechin gallate |
| 02/20/2008 | EP1888116A2 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones |
| 02/20/2008 | EP1888081A2 Compositions containing pufa and methods of use thereof |
| 02/20/2008 | EP1888045A2 Oral pharmaceutical composition for treating a cox-2 mediated condition |
| 02/20/2008 | EP1888029A2 Topical ungual formulations |
| 02/20/2008 | EP1578294A4 Methods and systems for enabling and stabilizing tooth movement |
| 02/20/2008 | EP1496908B1 Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer |
| 02/20/2008 | EP1421092A4 Neutral glycosphingolipids and glycosyl-sphingosines and methods for isolating the same |
| 02/20/2008 | EP1408966B1 Synergistic pharmaceutical combinations for the prevention or treatment of diabetes |
| 02/20/2008 | EP1404704B9 Bridged bicyclic serine protease inhibitors |
| 02/20/2008 | EP1359936B1 Combined use of factor vii polypeptides and factor viii polypeptides |
| 02/20/2008 | EP1285947B1 Antimicrobial composition |
| 02/20/2008 | EP1225915B1 Use of anti-il-2 polyclonal antibodies for the treatment of insulin-dependent diabetes mellitus and lupus erythematosus |
| 02/20/2008 | EP1171124B1 Anthelmintic compositions |